ZEIT.FINANCE

We will cure cancer

Medical science will achieve a cure, or major curative breakthroughs, for cancer.

Potential upside
+33%
Payout1.3×
per $1 · 1× = money back
Market odds77%
what the market priced this at when it was saved
1 of 4decided1confirmed

Bet timeline: 4 markets, 1 happened, first verdict Nov 3, 2026, last Dec 31, 2027

  • Skin cancer vaccine BLA submitted by June 30, 2027?, Jun 30, 2027 (in 9 months), still open
  • FDA approves Daraxonrasib this year?, Dec 31, 2026, happened
  • FDA approves skin cancer vaccine by...?, Dec 31, 2027 (in 15 months), still open
  • California Immunology Research Bond Proposition, Nov 3, 2026 (in 29 days), still open

Money back if its 2 biggest bets land. Next verdict Nov 3, 2026.

Build your own

Tracked since Aug 21 · −3.2% on paper

#10 of 38 ranked

Loading performance…

What has to be true

Every claim this book is built on, and what has happened to it so far.

What shows up first

  1. FDA approves a novel cancer therapy (e.g. mRNA vaccine or CAR-T) in the near termConfirmed

    This book backs

    YES

    What that looks like: FDA grants approval to a new cancer drug or vaccine

    • FDA approves Daraxonrasib this year?Yes90%now100%happened

    Confirmed Aug 26, 2026

  2. Moderna/Merck's mRNA-4157 cancer vaccine succeeds in Phase 3 trial75%today

    This book backs

    YES

    What that looks like: Moderna/Merck report positive mRNA-4157 Phase 3 data

    • Skin cancer vaccine BLA submitted by June 30, 2027?Yes87%now83%
    • December 31FDA approves skin cancer vaccine by...?68%now67%

    Markets price this at 75% today

  3. FDA grants breakthrough therapy designation to a new oncology drug

    This book backs

    YES

    What that looks like: FDA breakthrough therapy designation announced for a cancer drug

    No bet in this book covers this claim.

  4. NIH/National Cancer Institute funding for cancer research increases41%today

    This book backs

    YES

    What that looks like: Congress passes budget increasing NIH/NCI cancer research funding

    • California Immunology Research Bond PropositionYes52%now41%

    Markets price this at 41% today

What confirms it

  1. AI-driven drug discovery (e.g. AlphaFold-derived tools) advances a new cancer drug candidate to clinical trials

    This book backs

    YES

    What that looks like: AI-discovered oncology compound enters human trials

    No bet in this book covers this claim.

  2. CRISPR gene-editing therapy is approved for a cancer treatment

    This book backs

    YES

    What that looks like: Regulator approves a CRISPR-based oncology therapy

    No bet in this book covers this claim.

  3. Immunotherapy (checkpoint inhibitors) gains FDA approval for additional cancer types

    This book backs

    YES

    What that looks like: FDA expands checkpoint inhibitor approval to a new cancer indication

    No bet in this book covers this claim.

  4. Biotech sector index (e.g. XBI) rallies on oncology breakthrough news

    This book backs

    YES

    What that looks like: XBI biotech index posts a notable rally tied to cancer-drug news

    No bet in this book covers this claim.

What pays it off

  1. A leading oncology-focused pharma company's stock price rises significantly

    This book backs

    YES

    What that looks like: Moderna or peer stock rises sharply on cancer-drug success

    No bet in this book covers this claim.

  2. Overall cancer mortality rate continues to decline / cancer survival rates improve

    This book backs

    YES

    What that looks like: National cancer statistics report show falling mortality rate

    No bet in this book covers this claim.

  3. Pancreatic cancer, historically hard to treat, sees a major treatment breakthrough

    This book backs

    YES

    What that looks like: New therapy significantly improves pancreatic cancer survival in trial

    No bet in this book covers this claim.

  4. A Nobel Prize in Physiology or Medicine is awarded for cancer research

    This book backs

    YES

    What that looks like: Nobel committee names cancer researchers as laureates

    No bet in this book covers this claim.

If only some of it happens

Drag to see what a partial hit pays.

If 2 of these 4 outcomes occur →≈0.6×per $1
Stake back at 4 of 4

Worst case 0.1× · typically 0.6× · best case 1.2× per $1.

Pick which ones
BetWhat it adds per $1

What brings the money back

Money back · 2 of 4these 2 bets landing returns the full stake.

Markets priced these landing together at around 58%. : around 67%.

Any 4 of the 4 bets landing returns the stake, whichever 4 they are. The bets named above are the fastest route, not the only one.

Where the money sits

4 bets, ranked by how much of the stake each one holds.

+33%4 bets

Skin cancer vaccine BLA submitted by June 30, 2027?

47%1.2×

December 31

FDA approves skin cancer vaccine by...?

47%1.5×
Below a flat split

FDA approves Daraxonrasib this year?

3.0%1.1×

California Immunology Research Bond Proposition

3.0%1.9×

Bar length is share of the stake; the longest is 47%. The second rule marks an equal split.

The green marks the fewest bets that pay the whole stake back — 2 of 4.

All 4 bets, and how each is sized.

Think something different? Price it.

Build your own